Difference between revisions of "Chidamide (Epidaza)"
Jump to navigation
Jump to search
m (Text replacement - "http://www.ncbi.nlm" to "https://www.ncbi.nlm") |
m (→Also known as) |
||
| Line 10: | Line 10: | ||
==Also known as== | ==Also known as== | ||
| − | HBI-8000 | + | *'''Code name:''' HBI-8000 |
| + | *'''Brand name:''' Epidaza | ||
[[Category:Drug index]] | [[Category:Drug index]] | ||
| − | [[Category: | + | [[Category:Oral medications]] |
[[Category:HDAC inhibitors]] | [[Category:HDAC inhibitors]] | ||
[[Category:Peripheral T-cell lymphoma medications]] | [[Category:Peripheral T-cell lymphoma medications]] | ||
| − | [[Category: | + | [[Category:CFDA approved drugs]] |
Revision as of 21:24, 27 November 2017
Mechanism of action
HDAC inhibitor
Preliminary data
Peripheral T-cell lymphoma
- Shi Y, Dong M, Hong X, Zhang W, Feng J, Zhu J, Yu L, Ke X, Huang H, Shen Z, Fan Y, Li W, Zhao X, Qi J, Huang H, Zhou D, Ning Z, Lu X. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol. 2015 Aug;26(8):1766-71. Epub 2015 Jun 23. link to original article PubMed
History of changes in FDA indication
Not FDA approved, but is approved for use in China.
Also known as
- Code name: HBI-8000
- Brand name: Epidaza